Adalimumab biosimilar - Boehringer Ingelheim

Drug Profile

Adalimumab biosimilar - Boehringer Ingelheim

Alternative Names: BI-695501

Latest Information Update: 08 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Boehringer Ingelheim
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Rheumatoid arthritis
  • Phase III Crohn's disease; Plaque psoriasis

Most Recent Events

  • 12 Jul 2017 Boehringer Ingelheim initiates enrolment in the phase III VOLTAIRE-X trial for Plaque psoriasis (In adults, In the elderly) in USA
  • 12 Jul 2017 Boehringer Ingelheim plans a phase III trial for Plaque psoriasis (NCT03210259)
  • 27 Jun 2017 Boehringer Ingelheim completes a phase II trial for Rheumatoid arthritis (In adults, In the elderly) in USA, Poland (NCT02636907)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top